Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> China Pharma Providers
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
China Pharma Providers
Type:
CMO-API
Title:
Jiangsu Hengrui Medicine Co Ltd
Chinese
CSertification:
GMP
International
Certification:
DMF
Primary Location:
Other Cities
China
Contact Info:
n/a
Webpage:
www.hrs.com.cn
HQ
Contact Info:
No.145, Renmin Dong Lu, Xinpu Qu, Lianyungang, Jiangsu 222002, China
Tel: +86 518 8547 5661; 518 8547 5919
Fax: +86 518 8545 3845
Email: hrs@hrs.com.cn
Additional
Contact Info:
n/a
Description:
Founded in 1970, the company is an important antineoplastic, cardiovascular, analgesic and antibiotic medicine producer, and is listed on the Shanghai Stock Exchange (code: 600276).
The company has two factories: the old one is located at Xinpu, and the new one is located in the Economy-Technology Development Zone. The Xinpu factory is the main area for producing bulk APIs, but also has formulation capacity. The new (formulations) factory has an area of 30,000 sq. m., and has annual throughput of 50 mn injections, 2 mn lyophilized powders, 2 mn sterile split charging powder, 500 mn troches and 12 mn transfusion bags.
Important APIs such as ifosfamide, etoposide, mesna and thiotepa have been approved by the US FDA.
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit